Published: March 11, 2010
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
ROCKVILLE, Md. - (BUSINESS WIRE) - Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad
El-Hibri, its chairman and chief executive officer, has been named by
the World Trade Center Institute (WTCI) as one of Maryland's outstanding
international business leaders. Celebrating the spirit of global
ambition and excellence in international leadership, WTCI presents the
Maryland International Leadership Awards annually to leaders within the
state who exemplify entrepreneurial spirit, innovation, and global reach.
Mr. El-Hibri stated, "Across the globe and on a daily basis, the
Emergent team lives out the company mission of protecting life - a
commitment to make meaningful contributions to address unmet medical
needs especially in underserved markets. It is an honor to be recognized
for the work that we do and to receive this award on behalf of the team."
"Mr. El-Hibri recognizes the importance of global markets as key to
future growth. WTCI is pleased to showcase Mr. El-Hibri and Emergent
BioSolutions' many achievements and is honored to name him as one of
Maryland's 2010 International Business Leadership Award winners," said
Deborah M. Kielty, president and executive director of the World Trade
Center Institute.
WTCI was established in Baltimore in 1989 as a non-profit membership
organization to help connect Maryland to the globe. It is the region's
premier private sector international business partner and a member of
the World Trade Center Association, a family of 300 centers located in
vibrant business communities around the world.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
Emergent BioSolutions
Investors Contact:
Robert G.
Burrows
Vice President, Investor Relations
+1-301-795-1877
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt
Vice President, Corporate
Communications
+1-301-795-1800
SchmittT@ebsi.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
